After being awarded $1.6 billion in funding by the U.S. government as part of its fast-track COVID-19 vaccine program Operation Warp Speed – the largest deal made by the program – shares of Novavax surged 32% in one trading session. On the heels of this surge, do shares of Novavax have more room to run – or is there little…
Today’s article highlights two “compelling small-cap stocks that combine a low cost of entry with the Street’s backing.” More specifically, these two stocks – a biotech firm and a pharmaceutical company – are currently trading for less than $8 a share, have earned “Strong Buy” consensus analyst ratings, and boast significant upside potential. For more, CLICK HERE.
In the current market environment, the author of today’s article notes that “As a stock picker, it’s important to find areas where the risk and reward proposition is more positive,” and advises that “One of the areas where this is best exhibited is with emerging markets.” He proceeds to highlight three emerging market stocks trading at big discounts based on…
Biotech stocks have been experiencing a healthy bounce, with the largest ETF that tracks the group recently hitting an all-time high following the announcement from Moderna that it was seeing early positive results with its coronavirus vaccine candidate. Some traders are cautioning investors to “tread carefully” when it comes to buying in to biotech stocks at their current levels, however,…
With their own distinct risk and reward characteristics, foreign government bonds can be a useful addition to a diversified portfolio. But do they make sense for retirees now at a time when approximately 25% of the foreign bond market trades with negative yields? Surprisingly, they might — under the right circumstances. This is due to what the author of today’s…
Today’s article outlines a screening process whereby the over 7500 companies traded on U.S. exchanges are filtered down to five large-cap, dividend-paying companies currently trading at large discounts that may be especially attractive to investors over age 50 – or any income-seeking investor. Specifically, these five stocks “all have “A-” or better debt-rating, at least 10% dividend growth in the…
The ten stocks identified in today’s article may be nice stocks to trade for short-term profit, but you may not want to bet your retirement portfolio on them. Specifically, the author identifies ten stocks that he argues “are more likely to hurt your retirement than help it” as they lack what he sees as the critical feature for retirement stocks:…
When it comes to identifying attractive stocks, today’s article recommends following broker rating upgrades: “Brokers have in depth idea about what’s happening in a particular company, as they directly communicate with the top management. Also, they exhaustively go through the company’s publicly available documents and attend conference calls.” The authors screened for stocks that have seen broker rating upgrades in…